Oncothyreon to begin trading today on NASDAQ and TSX

About this update from Skrr Exploration, Inc.

[{"type":"text","content":"\n\n\n\nBELLEVUE, WA, Dec. 11 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY)\ntoday announced that its common stock will begin trading on the Nasdaq Global\nMarket under the symbol ONTY and on the Toronto Stock Exchange under the\nsymbol ONY at the opening of trading today. Oncothyreon Inc. is the new name\nfor the former Biomira Inc., as the result of a plan of arrangement under\nwhich Biomira has moved its jurisdiction of incorporation from Canada to the\nstate of Delaware in the United States. Shareholders of the former Biomira\nreceived one share of Oncothyreon common stock for each six shares of Biomira\nthat they held, and the trading price today will reflect this effective\nreverse split.\n\n\n"Today represents a major milestone in our plan for Oncothyreon to become\na leading developer of innovative therapeutic products in oncology," said\nRobert L. Kirkman, M.D. President and Chief Executive Officer of Oncothyreon.\n"Oncothyreon begins its new existence with a strong product pipeline of\ntherapeutic vaccines and targeted small molecules for the treatment of cancer.\nWe intend to focus on moving this pipeline forward as rapidly as possible,\nboth through internal efforts and potential partnerships, while we continue to\nseek new product opportunities through in-licensing and acquisition."\n\n\nAbout Oncothyreon\n\n\nOncothyreon is a biotechnology company specializing in the development of\ninnovative therapeutic products for the treatment of cancer. Oncothyreon's\ngoal is to develop and commercialize novel synthetic vaccines and targeted\nsmall molecules that have the potential to improve the lives and outcomes of\ncancer patients.\n\n\nForward-Looking Statements\n\n\nIn order to provide Oncothyreon's investors with an understanding of its\ncurrent intentions and future prospects, this release contains statements that\nare forward looking, including statements relating to the clinical development\nof its products and future business plans. These forward-looking statements\nrepresent Oncothyreon's intentions, plans, expectations and beliefs and are\nbased on its management's experience and assessment of historical and future\ntrends and the application of key assumptions relating to future events and\ncircumstances.\n\n\nForward-looking statements involve risks and uncertainties, including\nrisks an...

More updates from Skrr Exploration, Inc.